Concomitant administration of interleukin-2 during therapeutic vaccinations against cancer: The good, the bad, or the evil?

Mads Hald Andersen, Sine Reker Hadrup, Per thor Stratem, Julie Gehl, Poul Geertsen, Jürgen C. Becker

Research output: Contribution to journalLetterResearchpeer-review

Original languageEnglish
JournalJournal of Clinical Oncology
Volume23
Issue number22
Pages (from-to)5265-5267
Number of pages3
ISSN0732-183X
DOIs
Publication statusPublished - 2005
Externally publishedYes

Keywords

  • Cancer Research
  • Oncology
  • bleomycin
  • Freund adjuvant
  • gamma interferon
  • glycoprotein gp 100
  • granulocyte macrophage colony stimulating factor
  • interleukin 2
  • melan A
  • montanide isa 51
  • recombinant vaccine
  • survivin
  • synthetic peptide
  • tumor antigen
  • unclassified drug
  • cancer vaccine
  • adjuvant therapy
  • cancer immunization
  • CD4 CD8 ratio
  • CD8+ T lymphocyte
  • cell migration
  • clinical trial
  • delayed hypersensitivity
  • dose response
  • drug potentiation
  • electrochemotherapy
  • enzyme linked immunospot assay
  • human
  • letter
  • melanoma
  • multiple cycle treatment
  • peripheral lymphocyte
  • priority journal
  • protein expression
  • drug administration
  • immunology
  • note
  • skin tumor
  • Cancer Vaccines
  • CD8-Positive T-Lymphocytes
  • Drug Administration Schedule
  • Humans
  • Interleukin-2
  • Melanoma
  • Skin Neoplasms
  • ONCOLOGY
  • TUMOR-INFILTRATING LYMPHOCYTES
  • T-CELL RESPONSES
  • IDENTIFICATION
  • SURVIVIN

Cite this